Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA
文献类型：期刊论文
| 作者 | Shen, Jianan2; Sun, Huiping1,2; Meng, Qingshuo2; Yin, Qi2 ; Zhang, Zhiwen2; Yu, Haijun2; Li, Yaping2
|
| 刊名 | MOLECULAR PHARMACEUTICS
 |
| 出版日期 | 2014-10 |
| 卷号 | 11期号:10页码:3342-3351 |
| 关键词 | sorafenib survivin shRNA co-delivery hepatocellular carcinoma multidrug resistance |
| ISSN号 | 1543-8384 |
| DOI | 10.1021/mp4006408 |
| 文献子类 | Article |
| 英文摘要 | The development of multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) is one of the major obstacles for successful chemotherapy of HCC. Co-delivery of sorafenib (SF) and survivin shRNA (shSur) was postulated to achieve synergistic effects in reversing MDR, suppressing tumor growth and angiogenesis. For this purpose, in this work, SF and shSur co-loaded pluronic P85-polyethyleneimine/D-alpha-tocopheryl polyethylene glycol 1000 succinate nanocomplexes (SSNs) were first designed and developed for the treatment of drug resistant HCC. The experimental results showed that SSNs could achieve effective cellular internalization and shSur transfection efficiency, induce significant downregulation of the survivin protein, and cause remarkable cell arrest and cell apoptosis. The tube formulation assay demonstrated that SSNs completely disrupted the enclosed capillary networks formed by human microvascular endothelial cells. The in vivo antitumor efficacy showed that SSNs were superior to that of other treatments on drug resistant hepatocellular tumor models. Therefore, it could be an efficient strategy to co-deliver SF and shSur for therapy of drug resistant HCC. |
| WOS关键词 | LUNG-CANCER ; DOWN-REGULATION ; CELLS ; NANOPARTICLES ; INTERFERENCE ; BAY-43-9006 ; APOPTOSIS ; DISEASE ; PROTEIN ; TRENDS |
| 资助项目 | National Basic Research Program of China[2012CB932502] ; National Basic Research Program of China[2013CB932704] ; National Basic Research Program of China[2013CB932503] ; National Natural Science Foundation of China[81230029] ; Shanghai program[12nm0501300] |
| WOS研究方向 | Research & Experimental Medicine ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000342857000013 |
| 出版者 | AMER CHEMICAL SOC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/276886]  |
| 专题 | 药物制剂研究中心 |
| 通讯作者 | Li, Yaping |
| 作者单位 | 1.Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China 2.Chinese Acad Sci, Ctr Pharmaceut, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Shen, Jianan,Sun, Huiping,Meng, Qingshuo,et al. Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA[J]. MOLECULAR PHARMACEUTICS,2014,11(10):3342-3351. |
| APA | Shen, Jianan.,Sun, Huiping.,Meng, Qingshuo.,Yin, Qi.,Zhang, Zhiwen.,...&Li, Yaping.(2014).Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA.MOLECULAR PHARMACEUTICS,11(10),3342-3351. |
| MLA | Shen, Jianan,et al."Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA".MOLECULAR PHARMACEUTICS 11.10(2014):3342-3351. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。